Recurrent Glioblastoma: A Review of the Treatment Options
Glioblastoma is a disease with a poor prognosis. Multiple efforts have been made to improve the long-term outcome, but the 5-year survival rate is still 5–10%. Recurrence of the disease is the usual way of progression. In this situation, there is no standard treatment. Different treatment options ca...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-08-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/15/17/4279 |
| _version_ | 1797582767128576000 |
|---|---|
| author | Maria Angeles Vaz-Salgado María Villamayor Víctor Albarrán Víctor Alía Pilar Sotoca Jesús Chamorro Diana Rosero Ana M. Barrill Mercedes Martín Eva Fernandez José Antonio Gutierrez Luis Mariano Rojas-Medina Luis Ley |
| author_facet | Maria Angeles Vaz-Salgado María Villamayor Víctor Albarrán Víctor Alía Pilar Sotoca Jesús Chamorro Diana Rosero Ana M. Barrill Mercedes Martín Eva Fernandez José Antonio Gutierrez Luis Mariano Rojas-Medina Luis Ley |
| author_sort | Maria Angeles Vaz-Salgado |
| collection | DOAJ |
| description | Glioblastoma is a disease with a poor prognosis. Multiple efforts have been made to improve the long-term outcome, but the 5-year survival rate is still 5–10%. Recurrence of the disease is the usual way of progression. In this situation, there is no standard treatment. Different treatment options can be considered. Among them would be reoperation or reirradiation. There are different studies that have assessed the impact on survival and the selection of patients who may benefit most from these strategies. Chemotherapy treatments have also been considered in several studies, mainly with alkylating agents, with data mostly from phase II studies. On the other hand, multiple studies have been carried out with target-directed treatments. Bevacizumab, a monoclonal antibody with anti-angiogenic activity, has demonstrated activity in several studies, and the FDA has approved it for this indication. Several other TKI drugs have been evaluated in this setting, but no clear benefit has been demonstrated. Immunotherapy treatments have been shown to be effective in other types of tumors, and several studies have evaluated their efficacy in this disease, both immune checkpoint inhibitors, oncolytic viruses, and vaccines. This paper reviews data from different studies that have evaluated the efficacy of different forms of relapsed glioblastoma. |
| first_indexed | 2024-03-10T23:27:11Z |
| format | Article |
| id | doaj.art-e21686c39c8e4ae587985afd49de7699 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T23:27:11Z |
| publishDate | 2023-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-e21686c39c8e4ae587985afd49de76992023-11-19T07:55:35ZengMDPI AGCancers2072-66942023-08-011517427910.3390/cancers15174279Recurrent Glioblastoma: A Review of the Treatment OptionsMaria Angeles Vaz-Salgado0María Villamayor1Víctor Albarrán2Víctor Alía3Pilar Sotoca4Jesús Chamorro5Diana Rosero6Ana M. Barrill7Mercedes Martín8Eva Fernandez9José Antonio Gutierrez10Luis Mariano Rojas-Medina11Luis Ley12Medical Oncology Department, Ramon y Cajal University Hospital, 28034 Madrid, SpainMedical Oncology Department, Ramon y Cajal University Hospital, 28034 Madrid, SpainMedical Oncology Department, Ramon y Cajal University Hospital, 28034 Madrid, SpainMedical Oncology Department, Ramon y Cajal University Hospital, 28034 Madrid, SpainMedical Oncology Department, Ramon y Cajal University Hospital, 28034 Madrid, SpainMedical Oncology Department, Ramon y Cajal University Hospital, 28034 Madrid, SpainMedical Oncology Department, Ramon y Cajal University Hospital, 28034 Madrid, SpainMedical Oncology Department, Ramon y Cajal University Hospital, 28034 Madrid, SpainRadiotherapy Oncology Department, Ramon y Cajal University Hospital, 28034 Madrid, SpainRadiotherapy Oncology Department, Ramon y Cajal University Hospital, 28034 Madrid, SpainNeurosurgery Department, Ramon y Cajal University Hospital, 28034 Madrid, SpainNeurosurgery Department, Ramon y Cajal University Hospital, 28034 Madrid, SpainNeurosurgery Department, Ramon y Cajal University Hospital, 28034 Madrid, SpainGlioblastoma is a disease with a poor prognosis. Multiple efforts have been made to improve the long-term outcome, but the 5-year survival rate is still 5–10%. Recurrence of the disease is the usual way of progression. In this situation, there is no standard treatment. Different treatment options can be considered. Among them would be reoperation or reirradiation. There are different studies that have assessed the impact on survival and the selection of patients who may benefit most from these strategies. Chemotherapy treatments have also been considered in several studies, mainly with alkylating agents, with data mostly from phase II studies. On the other hand, multiple studies have been carried out with target-directed treatments. Bevacizumab, a monoclonal antibody with anti-angiogenic activity, has demonstrated activity in several studies, and the FDA has approved it for this indication. Several other TKI drugs have been evaluated in this setting, but no clear benefit has been demonstrated. Immunotherapy treatments have been shown to be effective in other types of tumors, and several studies have evaluated their efficacy in this disease, both immune checkpoint inhibitors, oncolytic viruses, and vaccines. This paper reviews data from different studies that have evaluated the efficacy of different forms of relapsed glioblastoma.https://www.mdpi.com/2072-6694/15/17/4279glioblastomarecurrent glioblastomabrain tumorglioblastoma chemotherapyimmunotherapyglioblastoma radiotherapy |
| spellingShingle | Maria Angeles Vaz-Salgado María Villamayor Víctor Albarrán Víctor Alía Pilar Sotoca Jesús Chamorro Diana Rosero Ana M. Barrill Mercedes Martín Eva Fernandez José Antonio Gutierrez Luis Mariano Rojas-Medina Luis Ley Recurrent Glioblastoma: A Review of the Treatment Options Cancers glioblastoma recurrent glioblastoma brain tumor glioblastoma chemotherapy immunotherapy glioblastoma radiotherapy |
| title | Recurrent Glioblastoma: A Review of the Treatment Options |
| title_full | Recurrent Glioblastoma: A Review of the Treatment Options |
| title_fullStr | Recurrent Glioblastoma: A Review of the Treatment Options |
| title_full_unstemmed | Recurrent Glioblastoma: A Review of the Treatment Options |
| title_short | Recurrent Glioblastoma: A Review of the Treatment Options |
| title_sort | recurrent glioblastoma a review of the treatment options |
| topic | glioblastoma recurrent glioblastoma brain tumor glioblastoma chemotherapy immunotherapy glioblastoma radiotherapy |
| url | https://www.mdpi.com/2072-6694/15/17/4279 |
| work_keys_str_mv | AT mariaangelesvazsalgado recurrentglioblastomaareviewofthetreatmentoptions AT mariavillamayor recurrentglioblastomaareviewofthetreatmentoptions AT victoralbarran recurrentglioblastomaareviewofthetreatmentoptions AT victoralia recurrentglioblastomaareviewofthetreatmentoptions AT pilarsotoca recurrentglioblastomaareviewofthetreatmentoptions AT jesuschamorro recurrentglioblastomaareviewofthetreatmentoptions AT dianarosero recurrentglioblastomaareviewofthetreatmentoptions AT anambarrill recurrentglioblastomaareviewofthetreatmentoptions AT mercedesmartin recurrentglioblastomaareviewofthetreatmentoptions AT evafernandez recurrentglioblastomaareviewofthetreatmentoptions AT joseantoniogutierrez recurrentglioblastomaareviewofthetreatmentoptions AT luismarianorojasmedina recurrentglioblastomaareviewofthetreatmentoptions AT luisley recurrentglioblastomaareviewofthetreatmentoptions |